$VentriPoint Diagnostics Ltd (VPT.CA)$recently announced their joint venture with General Electric Healthcare to place their software on GE's ultrasound machines. Just capturing 1% of this specific market is $2,000,000,000 in sales.
There are many positive catalysts for Ventripoint. Firstly, any investment in the company is substantially de-risked given that the product is already developed with regulatory approvals and sales are already underway.
Its current valuation of USD$50 million is also small change for large players and this may result in an attractive exit strategy if an acquisition goes through.
Compare Ventripoint against its peers - the Nasdaq-listed $Nano X Imaging (NNOX.US)$ with a market cap of US$1.57 Billion. The potential is huge!